GLP-1 Nausea: A Guide to Managing Nausea from GLP-1 Medications

GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® have proven to be incredibly successful, both for treatment of type 2 diabetes and for weight loss.

While their efficacy can’t be denied, they can come with a common side effect: nausea.

Nausea, or feeling like you might vomit, often comes from stomach flu, motion sickness, pregnancy, or stress, but can also strike when you first start using GLP-1s or increase your dosage.

Fortunately, it is rarely serious. I’ll explain how to manage it with a multifaceted approach that includes new eating habits, anti-nausea meds, home remedies, and more.

Putting GLP-1 Side Effects Into Perspective

It’s important to note that although GLP-1s can certainly cause side effects, so can obesity, and the side effects of obesity can often be far more serious than nausea.

Health risks associated with obesity include type-2 diabetes, high blood pressure, stroke, heart disease, some types of cancers, as well as a significant mental toll.^[1] 

In fact, studies show that obesity is second only to smoking in preventable causes of death in the US.^[2] 

Understanding Why GLP-1 Medications Cause Nausea

To understand how to combat nausea caused by your GLP-1 medication, we should start with the two main causes of GLP- nausea.

Cause 1: Delayed Gastric Emptying

GLP-1s slow down your digestive process, so food remains in your stomach longer before moving on to your small intestine. The longer the food stays in your stomach, the less hungry you are and the less you eat.

This is why GLP-1s are so effective, but it’s also one reason why they can cause nausea. If food sits in your stomach for too long, you may start to feel as if you are going to vomit. You also may feel bloated, have stomach cramps, or get acid reflux.^[3]

This is most common when you first start taking GLP-1s or when you increase your dosage. Since you’re not used to the effects of the GLP-1, you may habitually eat more than your stomach now feels comfortable with, which will cause discomfort.

The nausea associated with delayed gastric emptying typically diminishes as your body adjusts to your new dosage.^[4]

Cause 2: Neurogenic Origin

Although we have a basic understanding of how GLP-1 drugs work on blood sugar and appetite, we still don’t fully understand why they cause nausea. Studies suggest that GLP-1s may cross the blood-brain barrier, which means they could affect the central nervous system.^[5]

Nausea can also develop in the brain and central nervous system, rather than the digestive system.^[6] For example, some people get nauseated due to anxiety or because of certain smells or sights that have no effect at all on the digestive system. This is nausea caused by the nervous system.

GLP-1s may affect the part of the brain known as the area postrema. This is the same part of the brain from which this type of nausea can derive.^[7] 

So, although we don’t fully understand the connection, we do know that in some cases, GLP-1-related nausea originates from this interaction with our central nervous system.

Nausea With GLP-1s: Prevalence, Timing, and Triggers

Now that we understand why people taking GLP-1s experience nausea, let’s go through some of the facts about GLP-1s and nausea as we currently understand them.

How Common Is It?

A number of studies have researched the prevalence of nausea with GLP-1 use, with a fairly wide range of results. Some studies claim as many as 50% of GLP-1 patients experience at least some nausea.^[8] However, the true number is probably lower.

Pinning down an exact percentage is difficult because of the many factors involved in measuring nausea in GLP-1 users:

• GLP-1 in question
• starting dosage 
• diet
• dosage compliance
• use of anti-nausea meds
• individual definitions of nausea 

The most comprehensive studies have shown that between 40%–65% of GLP-1 patients experience nausea and/or other digestive disturbances, like diarrhea and vomiting.^[9] 

A study conducted reported on the FDA label for Wegovy (semaglutide) included more than 2,000 patients and found that 44% of them experienced nausea.^[10] And clinical trials for Zepbound (tirzepatide) found that 56% of patients experienced gastrointestinal adverse reactions.^[11] 

When Does It Occur?

GLP-1 related nausea is most common when you first begin your medication because it can take your body a while to adjust.^[8] 

Some patients who use GLP-1s report that nausea occurs after every injection, even after they’ve been taking them for months. However, it’s more likely to happen during or right after increasing the dose.^[12] 

How Long Does Nausea Typically Last?

There’s a wide range of nausea duration for those unfortunate enough to experience it.

Some patients have some degree of nausea for the first four to five weeks of treatment, but in many cases, symptoms disappear within eight days of beginning treatment. Overall, nausea tends to decrease after taking the medication consistently for several months.

Since everyone reacts to the medication differently, how long nausea lasts can vary.

How Bad Does It Usually Get?

GLP-1 related nausea is rarely so bad that it causes concern. A comprehensive study found that more than 99% of adverse digestive effects associated with GLP-1s are non-serious.^[13] 

For most patients, mild nausea is the only side effect they’ll experience, and for many of them the effects will dissipate as their bodies adjust to GLP-1 use.

In rare cases, nausea can become severe and occur alongside vomiting, diarrhea, and dehydration. In these cases, which I discuss further in our red flags section, you’ll want to consult your doctor as soon as possible.

Common Triggers

There are certain triggers that also may give you nausea, even after you’ve adjusted to GLP-1 use.

Meal-Related Nausea

GLP-1s work by making you feel full quicker, but you may be tempted to continue eating even after you’re full. Maybe it’s because the food is just so good, maybe you’re still eating your usual portion size, or maybe you’re in a social setting and feel compelled to finish your grandma’s special apple pie.

Whatever the reason, you can still indulge too much even on a GLP-1, which means a stomach that already thinks it is full will feel even fuller, often leading to nausea.

Food-Related Nausea

A lot of people think they can eat whatever they want with GLP-1s and still lose weight. This is not necessarily true, especially if you’re trying to prevent nausea.

High-fat and high-sugar foods like pizza, burgers, french fries, and sugary desserts take longer to digest than other foods, so they are already in your stomach for an extended period of time. If you add that to the delaying effect of GLP-1s, your nausea may increase.^[14] 

Sporadic Nausea

The neurogenic origin of GLP-related nausea (and nausea in general) means that nausea can occur at seemingly random times, with no connection to food consumption.

Managing and Preventing Nausea

The best way to mitigate or completely eliminate nausea from your GLP-1 meds is to take a multi-faceted approach. Combining the following strategies, with your doctor’s guidance, could significantly reduce any nausea you may feel.

Foundational Strategy: Proper Dose Titration

Since nausea is most prevalent at the beginning of treatment, it is paramount that you start your weight-loss journey with a trustworthy GLP-1 provider who will get you started as safely as possible 

That typically means starting at a low dosage and gradually working your way up to higher doses.

This can be harder than it sounds simply because of the temptation to try to lose as much weight as quickly as possible.

However, studies show that GLP-1 patients who start at lower doses are less likely to experience nausea and are far less likely to quit their program due to side effects. Furthermore, those that started at lower doses ended up losing almost the same amount of weight as those that began at a higher dose.^[15]

The lesson: Slow and steady wins the race (or at least ties, albeit with far less nausea).

It’s also important not to increase your dosage until side effects from your lower dosage have subsided. Work closely with your provider and stick with a dose until your body has completely adjusted. Only then should you step up your dosage, if necessary.

Dietary and Behavioral Modifications

Despite the incredible effects of GLP-1 medication, you still have to alter your diet if you want long term success. You have to help your body adjust to your medication.

Here are some simple changes you can make that will help mitigate nausea and keep you on your weight-loss journey

Changing Your Eating Habits 

Changing how you eat your meals can considerably decrease the likelihood of nausea.

Simple adjustments like eating four or five smaller meals throughout the day rather than the standard three larger meals may help avoid overwhelming your stomach.^[16]

Psychologists studying the mental effects of GLP-1s also suggest eating more mindfully, which means eating slowly and savoring each bite. This allows you to pay more attention to your body’s cues and stop eating before you’ve overdone it.^[17] 

Providers also emphasize the importance of recognizing these cues and stopping eating once you feel full. “Full” means when your stomach feels satisfied, not when you feel like you’ve had a large meal. If you eat past satisfied, you have a higher risk of nausea.^[18] 

According to gastroenterologists, even changing your posture while eating or immediately after can affect your rate of digestion. Slouching can compress your stomach, but eating with a straight back and standing up and raising your arms after eating can be surprisingly helpful.^[19]

It’s also helpful to avoid distractions, like watching TV while you eat, so you can pay more attention to your body’s signals and won’t habitually eat more than your body now desires.^[8]

Making Careful Food Choices

At the beginning of your treatment, doctors suggest focusing on simple, easy-to-digest foods with adequate protein and fiber. As your body adjusts, you can begin to expand your diet and see what works for you.^[20]

Strictly avoid very heavy, fatty, and greasy foods. Studies have shown that heavy foods linger in your stomach, so adding slow-digesting foods to your GLP-1 medications is often a recipe for nausea.^[20] 

Consuming too much protein can also cause problems for GLP-1 users. While it’s true that getting enough protein is critical to maintaining muscle mass while taking GLP-1s, many protein sources are high in fat. Doctors suggest eating protein from lower fat sources, such as blue fish and white meats.^[16]

Keeping a food diary is an excellent way to see which foods trigger nausea for you personally and which don’t.

Injection Timing and Location

According to GLP-1 manufacturers, you take your injection at any time of day.^[21] Anecdotally, however, many users have found that injecting themselves at different times of day can cause different levels of nausea. Some do better injecting themselves in the morning, others at night.

Some have also reported that where they make their injections also has an impact on how they feel. Injecting yourself in the arm rather than the abdomen or legs might make a difference.

There is no universally accepted best time and place for your injections, so you’ll only know through trial and error, but making adjustments can help.

Drinking Plenty of Water

Drinking water is an essential part of healthy digestion and can be particularly helpful while your body adjusts to GLP-1s. Water helps lubricate your digestive tract, makes it easier for your body to absorb nutrients, and can prevent constipation.^[22]

Medication-Based Solutions (Under Doctor’s Supervision)

If you can’t mitigate your side effects by making some lifestyle changes, medical and home remedy options might be able to help you.

Always consult with your provider before beginning supplementary nausea remedies.

Home Remedies

Some of the more common and effective home remedies for nausea contain ginger or peppermint. Any teas, candies, gums, or recipes containing either ingredient might help.

The National Health Service of the UK also suggests such simple things as getting lots of fresh air or trying to distract yourself with television or music.^[23] 

The only problem with home remedies is that they are often hit-or-miss, so you may have to try a few before you find one that works for you.

Over-the-Counter Medications and Treatments

Double check with your doctor first, but in most cases over-the-counter anti-nausea medications can be taken with your GLP-1.

Gravol, Tums, Imodium, and Pepto Bismol are not considered to have contraindications with GLP-1s taken for weight loss.^[24] However these are not long-term solutions and should only be used occasionally with your doctor’s guidance.

Acupuncture has also been shown in studies to help control nausea, and it may even be covered by your insurance, so check your policy.^[25] 

Prescription Anti-Nausea Medications

Nausea can be more disruptive for some than for others. For example, someone working from home will be less affected by occasional nausea than a flight attendant.

If you are someone for whom nausea would be extremely disruptive, your doctor may offer prescription medication.

Some common anti-nausea prescription drugs include ondansetron, which is sold under the name Zofran. Zofran is an oral dissolving tablet often used for those who experience nausea related to cancer treatments, but it can be effective in preventing GLP-1-related nausea as well. It works by blocking certain signals between the stomach and the brain involved in nausea.^[26] 

If your nausea is particularly severe, your doctor may prescribe metoclopramide (Reglan). Reglan increases motility, which means it helps move food through your digestive tract, which can eliminate some of the causes of nausea but may also lessen the effect of your GLP-1.

Microdosing

GLP-1 microdosing is becoming an increasingly popular way to potentially limit extreme side effects of GLP-1s. Microdosing simply means taking less than is typically prescribed.

There is not yet a lot of evidence regarding the efficacy of microdosing GLP-1s, and no microdose of a GLP-1 has FDA approval, so check with your doctor for the latest recommendations before starting a microdosing program.

Switching GLP-1 Medications

Some people may find certain GLP-1s are easier on their system than others. If you are taking semaglutide like Wegovy, you may benefit from a switch to tirzepatide (Zepbound).

Tirzepatide is a dual GLP/GIP agonist, while semaglutide is only a GLP-1 agonist. Some studies indicate that the GIP component may make patients less nauseous than those taking a GLP-1 agonist alone.^[27] However, the FDA found more patients on tirzepatide had nausea, perhaps because doctors often prescribe tirzepatide at higher doses due to its high tolerability.

Either way, if you’re experiencing nausea on one GLP-1, talk to your doctor about potentially making a switch.

Red Flags: When to Contact Your Doctor

There’s a difference between nuisance side effects like occasional nausea or diarrhea and serious side effects that could cause permanent damage.

If you have any of the following contact your doctor or GLP-1 provider.

Worsening Nausea

Once again, it is worth noting that GLP-1s do not function because they cause nausea that discourages you from eating. Nausea should be nothing more than a temporary side effect.

If your nausea does not subside or starts to get worse the longer you’re on your medication, you should consult your provider.

While everyone deals with nausea from time to time, continuous, long-term nausea can take a toll on your quality of life.^[28] 

Inability to Eat

You should still be able to eat on GLP-1s—you should just feel full after eating less.

If you feel so nauseous that you can’t eat, you may be opening yourself up to a host of more serious long-term complications.

Not eating enough can lead to dehydration and malnutrition, both of which can have severely negative effects on your immune system, cardiovascular system, and digestive system.^[29] 

Before Surgery

If you are scheduled for surgery, be certain to notify your doctors that you are taking GLP-1s. Anesthesia requires an empty stomach, and since GLP-1s delay that emptying, you may be required to quit using the GLP-1 a few days before your procedure.^[30] 

Vomiting

Vomiting is also a fairly common side effect of GLP-1s. One study indicates that it will affect nearly 22% of GLP-1 patients.^[31] 

So, if you vomit, particularly after your first dose, you are not alone. However, if vomiting persists or prevents you from eating, see your doctor as soon as possible. If there is blood in your vomit, immediately seek medical help because this could indicate something serious, such as inflammation of the pancreas (pancreatitis).^[32]

Severe Stomach Pain

There’s a difference between nausea and pain. Nausea is more like the feeling of sea sickness, not cramps or pain. If you are experiencing severe, long-lasting abdominal pain, contact your doctor immediately. This may be another sign of pancreatitis.^[33]

Severe abdominal pain combined with the inability to pass gas or stool could also indicate a bowel obstruction, which is a very rare but very serious side effect that should be attended to immediately.^[34] 

Conclusion: Finding Your Balance for Sustainable Success

The goal of GLP-1s is to lose weight or help you manage diabetes. Achieving these goals could have a profound impact on your physical and mental health, but managing nausea is a common obstacle.

Let your body slowly adjust to smaller doses, change your eating habits to let the GLP-1s have their intended effect, and keep in touch with your healthcare team.

If you can find the right balance and feel good while using a GLP-1, you have a great chance of comfortably and successfully reaching your long-term weight-loss goals.

FAQs

Sources

1. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Health risks of overweight and obesity. National Institutes of Health, US Department of Health and Human Services. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks
2. Goldman, D. (2020). Obesity, second to smoking as the most preventable cause of US deaths, needs new approaches. USC Leonard D. Schaeffer Institute for Public Policy & Government Service. https://schaeffer.usc.edu/research/obesity-second-to-smoking-as-the-most-preventable-cause-of-us-deaths-needs-new-approaches/
3. Noh, Y., Yin, H., Yu, O. H., Bitton, A., & Azoulay, L. (2025). Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: A population-based cohort study. Annals of Internal Medicine, 178(9), 1268–1278. https://doi.org/10.7326/ANNALS-24-03420
4. Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2015). Adverse effects of GLP-1 receptor agonists. The Review of Diabetic Studies, 11(3), 202. https://pubmed.ncbi.nlm.nih.gov/26177483/
5. West, J., Li, M., Wong, S., Le, G. H., Teopiz, K. M., Valentino, K., Dri, C. E., & McIntyre, R.S. (2025). Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) Penetrant: A narrative review. Neurology and Therapy, 14, 1–10. https://doi.org/10.1007/s40120-025-00724-y
6. Zhang, C., Kaye, J. A., Cai, Z., Wang, Y., Prescott, S. L., & Liberles, S. D. (2021). Area postrema cell types that mediate nausea-associated behaviors. Neuron, 109(3), 461–472. https://doi.org/10.1016/j.neuron.2020.11.010
7. Fulton, S., Horn, C. C., & Zhang, C. (2024). Characterizing a new tool to manipulate area postrema GLP1R+ neurons across species. Physiology & Behavior, 276, 114474. https://doi.org/10.1016/j.physbeh.2024.114474
8. Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., & Górriz, J. L. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
9. Drucker, D. J. (2024). Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care, 47(11), 1873–1888. https://doi.org/10.2337/dci24-0003
10. US Food & Drug Administration. (n.d.). Wegovy. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
11. US Food & Drug Administration. (2025, September 16). Warning letter: Eli Lilly and Company, MARCS-CMS 716485 — September 09, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716485-09092025
12. Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., & Pedersen, S. D. (2022). Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, 24(1), 94–105. https://doi.org/10.1111/dom.14551
13. Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., & Pedersen, S. D. (2022). Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, 24(1), 94–105. https://doi.org/10.1111/dom.14551
14. Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2025). Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. The Journal of Clinical Endocrinology & Metabolism, 110(1), 1–15. https://doi.org/10.1210/clinem/dgae719
15. Eldor, R., Avraham, N., Rosenberg, O., Shpigelman, M., Golan-Cohen, A., Cukierman-Yaffe, T., Merzon, E., & Buch, A. (2025). Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: A randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen. Diabetes Care, 48(9), 1607–1611. https://doi.org/10.2337/dc25-0690
16. Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024). Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist. Diabetes, Metabolic Syndrome and Obesity, 4817–4824. https://doi.org/10.2147/DMSO.S494919
17. Krug, I., Dang, A. B., Portingale, J., Li, Y., & Won, Y. Q. (2025). Beyond weight loss: GLP-1 usage and appetite regulation in the context of eating disorders and psychosocial processes. Nutrients, 17(23), 3735. https://doi.org/10.3390/nu17233735
18. Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14–19. https://doi.org/10.1080/00325481.2021.2002616
19. Harvard Health Publishing. (2023, July 20). 2 surprising risks of poor posture. Harvard Medical School. https://www.health.harvard.edu/staying-healthy/3-surprising-risks-of-poor-posture
20. Mehrtash, F., Dushay, J., & Manson, J. E. (2025). I am taking a GLP-1 weight-loss medication—what should I know? JAMA Internal Medicine, 185(9), 1180–1180. https://doi.org/10.1001/jamainternmed.2025.1133
21. NovoMedlink. (n.d.). Dosing & administration: The Wegovy® pen. https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/the-wegovy-pen.html
22. Mayo Clinic. (n.d.). Nutrition and healthy eating. https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/expert-answers/digestion/faq-20058348
23. National Health Service. (n.d.). Feeling sick (nausea). https://www.nhs.uk/symptoms/feeling-sick-nausea/
24. National Health Service. (n.d.). Who can and cannot take Pepto-Bismol. https://www.nhs.uk/medicines/pepto-bismol/who-can-and-cannot-take-pepto-bismol/
25. Streitberger, K., Ezzo, J., & Schneider, A. (2006). Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Autonomic Neuroscience, 129(1-2), 107–117. https://doi.org/10.1016/j.autneu.2006.07.015
26. MedlinePlus. (n.d.). Ondanstrenton. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a601209.html
27. Borner, T., De Jonghe, B. C., & Hayes, M. R. (2024). The antiemetic actions of GIP receptor agonism. American Journal of Physiology-Endocrinology and Metabolism, 326(4), E528–E536. https://doi.org/10.1152/ajpendo.00330.2023
28. Lacy, B. E., Parkman, H. P., & Camilleri, M. (2018). Chronic nausea and vomiting: evaluation and treatment. Official Journal of the American College of Gastroenterology, 113(5), 647–659. https://doi.org/10.1038/s41395-018-0039-2
29. Saunders, J., & Smith, T. (2010). Malnutrition: causes and consequences. Clinical Medicine, 10(6), 624–627. https://doi.org/10.7861/clinmedicine.10-6-624
30. Harvard Health Publishing. (2024, February 5). GLP-1 diabetes and weight-loss drug side effects: “Ozempic face” and more. Harvard Medical School. https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more
31. Liu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022). Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Frontiers in Endocrinology, 13, 1043789. https://doi.org/10.3389/fendo.2022.1043789
32. Cleveland Clinic. (n.d.). Vomiting blood. https://my.clevelandclinic.org/health/symptoms/17708-vomiting-blood
33.  Guy’s and St Thomas’ NHS Foundation Trust. (n.d.). Diabetes medicines: GLP-1 agonists. National Health Service. https://www.guysandstthomas.nhs.uk/health-information/diabetes-medicines-glp-1-agonists
34. Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2025). Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. The Journal of Clinical Endocrinology & Metabolism, 110(1), 1–15. https://doi.org/10.1210/clinem/dgae719